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Abstract 
OBJECTIVE: Sinonasal undifferentiated carcinoma (SNUC) is an aggressive malignancy first described by 
Frierson et al. in 1986. As the tumor is very rare, current treatment recommendations are based on institutional 
case reports. We thus felt the need to perform a comprehensive systematic review and meta-analysis to 
investigate how treatment modalities are associated with survival. 
DESIGN: Case-series, systematic review and meta-analysis 
METHODS: We searched the OvidMedline, OvidEmbase, Web of Science, Biosis, Scopus and the Cochrane 
Library database libraries. We extracted aggregate and individual patient data for statistical analysis. To study 
the association between treatment modalities and survival, we used random-effects meta-regression for the 
aggregate- and cox mixed-effects models. 
RESULTS: 379 citations were found; 29 case series could be included in the final analysis, including a total 
number of 390 single patients (34.6% female). Median age at diagnosis was 52 years. 80.9% of patients 
presented with a T4 tumor and 16.0% with nodal metastasis at diagnosis. In individual patient data (IPD) meta-
analysis, single modality (surgery alone or radiation alone) treatment was associated with reduced survival 
compared to double modality (surgery & radiation or chemoradiation) treatment (adjusted Hazard Ratio [aHR] 
2.97, 95% ConfidenceInterval [1.41-6.27]) and compared to triple modality (surgery & radiation & 
chemotherapy) treatment (aHR 2.80 95%-CI 1.29-6.05 for triple vs. single modality). Triple modality treatment 
was not superior to double modality treatment. (aHR 1.06, 95%-CI 0.59-1.92). 
CONCLUSION: Double and triple modality treatment are associated with improved survival over single 
modality but there is no evidence that triple modality is superior to double modality treatment.    
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Introduction 
Sinonasal undifferentiated carcinoma (SNUC) is a rare malignancy first described by Frierson et al.[1] in 1986. 
Frierson already recognized the aggressive behaviour of this malignancy, describing a median survival of 4 
months in his series, where the vast majority of patients were treated with radiotherapy alone[1]. According to 
data from the Surveillance, Epidemiology, and End Results (SEER) database, the estimated incidence rate of 
SNUC is 0.02 per 100'000[2]. Histologically, SNUC is defined as a small round blue cell tumor that is 
immunohistochemically distinct from other sinonasal malignancies, such as lymphoma, mucosal melanoma, 
nasopharyngeal carcinoma, neuroendocrine carcinoma, and olfactory neuroblastoma[1]. Therefore, staining for 
leucocyte common antigen (LCA), S-100 protein, vimentin, in situ hybridization for Ebstein-Barr encoded 
RNA (EBER), synaptophysin and calretinin are typically negative while cytokeratins stain positive[3]. 
The management of SNUC is challenging as these tumors are located in areas difficult to reach, since they arise 
from the sinonasal cavity with frequent invasion of critical nearby structures such as the skull base or orbit. The 
traditional surgical management for those tumors is open craniofacial resection. A potential advantage of open 
surgery consists of approaching the tumor from around its healthy surrounding, dissecting towards the tumor, 
allowing en bloc resection and accurate margins assessment[4]. However, full open resection of gross disease 
can be linked to severe morbidity with uncertain benefit on survival. In recent years the advent of endoscopic 
sinus and skull base surgery for selected cases resulted in a dramatic decrease in morbidity, and might thus 
offer better quality of life in patients showing a poor prognosis[5]. Similarly to surgery for SNUC in general, 
the exact advantage of radiotherapy and chemotherapy in the primary or (neo-) adjuvant setting remains 
unclear. This lack of consensus can be explained by the rarity of the disease, which renders clinical trials 
difficult to perform in practice[6]. Consequently, current treatment regimens are based on small institutional 
case-series and differ widely[7]. Another issue is the management of the neck, as SNUC appears to show 
higher propensity to nodal metastasis than other sinonasal malignancies[7]. 
We therefore felt the need to perform a comprehensive systematic review and meta-analysis of the literature to 
investigate how treatment modalities are associated with survival and if elective treatment of the neck is 
justified. In addition, we present an institutional case-series of SNUC patients from the University Hospital 
Zurich. 
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Data and Methods 
Data 
Institutional case series 
We performed a retrospective study in SNUC patients treated at the Department for Otorhinolaryngology – 
Head and Neck Surgery of the University Hospital Zurich, Zurich, Switzerland. We examined charts to obtain 
detailed demographic and clinical data (sex, age, TNM stage, lymph node involvement, orbit and skull base 
invasion, treatment modalities, follow-up and recurrence). Data were anonymized according to ethical 
guidelines. We included only cases with histologically and immunohistochemically verified SNUC in the 
analysis. A Swiss Medical Association (FMH) board certified pathologist (KI) reviewed all cases to ensure the 
accuracy of the diagnosis. Staging was performed according to the American Joint Committee on Cancer 
(AJCC), TNM Staging for sinonasal  cancer, 7th edition 2010[8]. All patients were presented at the local 
interdisciplinary tumor board and treatment recommendation was based on the available guidelines and 
literature at the time of the patients' accrual. This study was approved by the local Ethics committee (Protocol 
number 2016-0162). 
 
Systematic review 
We extracted information from all eligible publications using a standardised data extraction sheet and report the 
review according to PRISMA guidelines[9]. We searched for studies in the electronic databases OvidMedline, 
OvidEmbase, Web of Science, Biosis, Scopus, and the Cochrane Library using a strategy elaborated with the 
help of a medical librarian (Suppl. Table 1). In order not to miss any appropriate study, we did not apply any 
time or language limits in our search. The reference lists of review articles were screened for potentially 
eligible studies. Case reports were excluded.  
The selection of studies involved an initial screening of the title and the abstract. In doubtful cases we obtained 
the full text. We entered articles in a data management software and eliminated the duplicates (Endnote 6®, 
Thompson Reuters Inc.). Two independent investigators (G.B.M. and D.V.) assessed information about 
participants (number of patients, study location(s), demographic variables), exposure and outcomes (treatment 
modality, recurrence, survival) and extracted it according to a detailed chart (Suppl. Table 2). 
 
Statistical methods 
Institutional Case series 
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We describe the case series and calculated median, regional, distant metastasis-free, and disease-specific 
survival at 2 and 5 years using Kaplan-Meier methods.  
 
Meta-analysis 
To assess the association between treatment modality and survival time we analyzed the data from the literature 
search in two steps: first, we run a meta-analysis for the aggregate (summary) data of all publications. Then we 
performed an individual participant data (IPD) meta-analysis for those studies reporting data on individual 
patients[10]. For both analyses we included the data of our institutional case series as well.  
For the aggregate meta-analysis we used 2-year-overall survival as outcome of interest, as it was the summary 
outcome measure most frequently reported at study level. If the 2-year survival was not reported for a study 
where IPD data could be extracted, we calculated it using the Kaplan-Meier method. The exposure was defined 
as the treatment combination composition of a study. For this we calculated for each study the percentage of 
patients in the treatment groups “palliative”, “surgery alone or radiotherapy alone”, "chemoradiation", “surgery 
& radiotherapy”, and “surgery & radiotherapy & chemotherapy”. As these percentages add up to 100% for 
each study, we applied the isometric log-ratio transformation for compositional data to the exposure. The 
outcome was logit-transformed for a more accurate model fit. To study the association between the treatment 
composition of a study and its reported 2-year overall survival, we first represented the data graphically by 
plotting the (transformed) 2-year overall survival versus the pairwise log-ratios of treatment compositions. In a 
second step, we fitted a random-effects meta-regression model (linear model).  
For the IPD meta-analysis, we used disease-specific survival-time (time until disease-specific death of a 
patient) as outcome, as this was the outcome most frequently reported on individual patient level. Patients that 
did not die were censored at the end of their follow-up time. The exposure was defined as the treatment of 
individual patients and was grouped into six categories: "palliative", "radiotherapy alone", "surgery alone", 
"chemoradiation", "surgery & radiotherapy ", "surgery & radiotherapy & chemotherapy". First, we plotted 
Kaplan-Meier curves stratified for the six different treatment categories for descriptive statistics. Then we fitted 
a univariable cox-mixed effects regression model (maximum likelihood optimization) including a random 
intercept on study-level and “treatment group” as single covariate. In a second step we also added the 
covariates “N”, “M1”, “age”, “T4” to adjust for possible confounders. As the categorization into six different 
treatment groups might result in groups including very few patients and events we then built contrasts 
comparing the treatment combinations "palliative", “single modality” (that is surgery alone or radiotherapy 
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alone), “double modality” (that is surgery & radiotherapy or chemoradiation), and “triple modality” (surgery & 
radiotherapy & chemotherapy).  
 
Results of statistical analyses are presented as medians with interquartile ranges (IQRs) or ranges, percentages, 
means and hazard ratios (HRs) with 95%-confidence intervals (95%-CIs).  
All analyses were carried out in SPSS® version 22.0.0 (IBM©, Armonk, NY, USA) and R version 3.2.3 (R 
Core Team, Vienna, Austria). 
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Results 
Institutional case series 
Table 1 shows detailed numbers for the retrospective institutional case series. It included eleven patients treated 
between 2001 and 2014 with a median age at diagnosis of 51 years (IQR 45-57.5). All patients were of 
Caucasian origin. Five patients were smokers, while three reported frequent drinking of alcohol. Five patients 
exerted professions with potential dust and chemicals exposition (Table 1). Most common symptom at 
presentation was facial pain and nasal congestion. Hyposmia, diploplia and loss of vision were reported rarely 
(in one patient each). Eight patients had a clinical T4 at diagnosis. No patients had evidence of regional or 
distant metastasis at diagnosis. Invasion of the orbits, the dura, and the brain was seen in six, five, and two 
respectively.  
Six patients were treated with open surgery, while two underwent endoscopic resection. All patients received 
postoperative adjuvant radiation with concomitant cisplatin, except for one patient that received adjuvant 
radiation only. One patient had induction chemotherapy with TPF (cisplatin, taxane, and 5FU) before surgery. 
Three patients were treated with primary radiation, two with concomitant chemotherapy (cisplatin), and one 
after induction chemotherapy by PF (cisplatin and 5FU). Intensity modulated radiotherapy (IMRT) was applied 
locally in all patients and to the neck nodes in 3 patients (Patient 4, 5, and 6). Mean radiation dose was 64.8 
Gray (SE 1.31) locally and 57.6 Gray (SE 4.17) regionally. Median follow-up time in the cohort was 17 months 
(IQR 11.5-64). Median disease-specific survival time was 21.4 months. 
 
Systematic review and meta-analysis 
The search retrieved 379 references published until January 20th, 2014: 26 from Biosis, 1 from the Cochrane 
Library, 39 from OvidMedline, 186 from OvidEmbase, 47 from Scopus, and 80 from Web of Sciences. 
Crosschecking the references of the reviews led to the inclusion of one supplementary article. A search update 
which was done on December 14th, 2015, led to the inclusion of 3 more articles (Figure 1). Overall 29 studies 
were included (Table 2). Noteworthy, we had to exclude 7 case series, as the cases reported showed overlap 
with previously published case series (Suppl. Table 3). For 19 (67.9%) out of the 29 included studies we could 
extract IPD. 
 
Study characteristics  
Published in final edited form as: Oral Oncol. 2017 Dec;75:28-34. doi: 10.1016/j.oraloncology.2017.10.008 
 7 
Including our case series, a total of 29 studies and 390 SNUC patients (34.6% female) were used for the meta-
analysis. Median age at diagnosis was 52 years (range 36[11] – 69[12]). Most patients presented with a T4 
tumor (80.9%), while 13.4% and 5.7% were T3 and T2/T1 tumors. Overall, an average of 16.0% of patients 
presented with nodal metastasis at diagnosis and 8.1% had evidence of distant metastasis. Overall, most 
patients had a triple modality treatment (“surgery & radiotherapy & chemotherapy” 36.2%), followed by 
double modality treatment ("chemoradiation" 26.0%, “surgery & radiotherapy” 16.9%) and single modality 
treatment (“surgery alone” or “radiotherapy alone” 16.0%). 5.0% of patients got palliative treatment only.  
 
The cumulative local, regional, distant metastasis-free, disease-specific and overall survival were 70.4%, 
73.1%, 75.5%, 55.4% and 51.5% at 2 years, and 69.6%, 79.4%, 63.4%, 37.4% and 36.4% at 5 years, 
respectively. Detailed results are shown in Suppl. Table 4.  
 
Aggregate data meta-analysis 
For the aggregate meta-analysis, we could use 20 out of the 29 studies (including 273 patients) because the 
other studies did not have complete reports on the 2-year overall survival or on the treatment composition 
(Table 3). The graphical representation of the data did not show any association between treatment 
compositions and survival (Suppl. Figure 1). It also revealed that there were very few studies that used all 
treatment modalities. As suspected graphically, when fitting the random effects meta-regression model, there 
was little evidence for a difference in 2-year overall survival related to treatment compositions (P=0.0789).  
 
IPD meta-analysis 
The 19 studies for which we could extract IPD included 232 patients. Out of these 19 studies, 17 studies (201 
patients) were included in the descriptive analysis and univariable meta-regression because they had complete 
data on survival and treatment modality; 11 studies (135 patients) with complete data on all variables were 
included in the multivariable regression analysis (Table 3). The Kaplan-Meier curves for disease-specific 
survival stratified for treatment modalities are shown in Figure 2. The dual modality treatment "surgery & 
radiotherapy" seemed to achieve the best outcome, followed by triple modality treatment (“surgery & 
radiotherapy & chemotherapy") and "chemoradiation". As expected, patients treated as "palliative" had the 
worst outcome. Crude HRs (with 95% CIs and corresponding P-values) from univariable cox mixed-effects 
regression analysis and adjusted HRs (aHRs) from multivariable regression analysis (adjusted for T, N, M and 
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age at diagnosis) comparing all treatment categories are shown in Table 4. Numerically, the aHRs for patients 
treated with “surgery & radiotherapy” was 3.97 (95% CI 1.27-12.42, P=0.018) compared to radiotherapy alone, 
and 3.92 (95% CI 1.19-12.92, P=0.025) when compared to surgery alone (Table 4). Similarly, patients treated 
with chemoradiation showed a better survival than patients treated with radiotherapy alone or surgery alone 
(aHR 2.55, 95% CI 1.12-5.80, P=0.037). In the unadjusted/univariable analysis, “surgery & radiotherapy” 
showed a trend towards superior outcome when compared to chemoradiation (HR 2.88, 95% CI 1.36-6.10, 
P=0.059). In the adjusted analysis, however, there was no statistical difference between “surgery & 
radiotherapy” and chemoradiation. The combination of “surgery & radiotherapy & chemotherapy” was not 
superior to “surgery & radiotherapy” and/or chemoradiation (Table 4). 
 
Similar results could be observed comparing single, double and triple modality treatment (Table 5): patients 
treated with a single modality treatment were about 2.7 times more likely to die than patients treated with 
double modality treatment (HR 2.43, 95%-CI 1.42-4.18; aHR 2.97, 95%-CI 1.41-6.27) and about 2.3 times 
more likely to die than patients treated with triple modality (HR 1,83, 95%-CI 1.02-3.28; aHR 2,80, 95%-CI 
1.29-6.05). There was no evidence that triple modality treatment was superior to dual modality treatment (HR 
[dual vs. triple modality] 0.75, 95%-CI 0.44-1.27; aHR 0.94, 95%-CI 0.52-1.70).  
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Discussion 
This study reports the clinical features and outcome of SNUC patients treated at a single institution and provides 
a systematic review and meta-analysis of the available literature on SNUC patients. We showed that combined 
treatment with surgery & radiotherapy or chemoradiation results in better disease-specific survival than surgery 
alone and radiotherapy alone. Interestingly, double modality treatment was always superior to single modality 
treatment but was not inferior to triple modality. 
Our study had several limitations. The validity of our meta-analysis might be limited as it is questionable if the 
differences seen in meta-analyses of observational studies are really due to different treatments or due to 
differences not captured in the model[13]. Although we tried to adjust for different confounders like severity of 
the disease and general health at diagnosis by including the covariates T, N, M, and age into multivariable 
analyses, these variables might not be able to capture the entire state of health of a patient. Also, many factors 
such as type of radiotherapy, dose of radiotherapy, type of chemotherapeutic agents used could not be 
integrated in the meta-analysis because of the large heterogeneity between studies. Further, the status of the 
surgical margins, pathologic risk assessment (perineural and/or lymphovascular invasion) as well the impact of 
elective neck treatment on locoregional control could not be examined, as these were only very rarely reported. 
This might result in another bias, as one may consider to renounce to adjuvant therapy after obtaining 
satisfactory surgical clearance of the tumor. Of note, we do not consider the type of surgery (open vs. 
endoscopic) per se to have a prognostic impact, as surgery is meant to provide maximal clearance of the tumor, 
independently of the method used[5]. These limitations notwithstanding, being the largest meta-analysis so far 
with nearly 400 patients, and the first one to comply with the PRISMA statement[9], were important strengths 
of our study. This enabled us to provide several important insights on SNUC characteristics, management, and 
outcome. 
First, we saw that almost two thirds of the SNUC patients were of male gender. Although SNUC has not been 
formally linked to professional exposure, the preponderance of male being affected by this disease suggests 
aetiological involvement of sexual hormones, smoking or occupational hazards[14]. Concerning the latter, 
exposure to several industrial compounds has been attributed to tumorigenesis in around 40% of all sinonasal 
cancers[15, 16]. Professionals working with wood have for example up to 500–900 times increased risk of 
developing sinonasal intestinal type adenocarcinoma[15]. For SNUC, the exact etiological agents have yet to 
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be identified. In our case-series, we didn't have any wood professionals, however five patients reported 
professional dust and chemical exposure (metallic hardware, cleaning products).  
 
Second, in our analyses, chemoradiation was always superior to radiotherapy alone. This suggests, as 
previously reported[7], that SNUC are chemosensitive. Whether the better disease-specific survival obtained by 
adding chemotherapy during radiation is due to radiochemosensitization of the tumor (thus enhancing 
locoregional control) or systemic effect (thus preventing distant dissemination of the tumor) is yet to be 
answered. Importantly, we could not analyse separately the different types of chemotherapy due to the great 
heterogeneity among studies reported so far. 
 
Third, we showed in multivariable analysis that patients with “surgery & radiotherapy” had better outcome 
than surgery alone. This suggest that combined treatment with surgical approach and postoperative 
radiotherapy should be offered, when surgical removal of gross disease is reasonably achievable. 
Further, patients treated with “surgery & radiotherapy” showed a trend towards a better outcome over 
chemoradiation in univariable but not in multivariable analysis. This difference may be explained by the fact 
that patients with advanced local disease with invasion of the orbits, skull base and brain involvement were 
more likely to be offered chemoradiation than “surgery & radiotherapy”, which resulted in an apparent poorer 
outcome in univariable, but not in multivariable (that is after adjusting for advanced T stage) analysis. Finally, 
although currently advocated by many authors[17], we failed to provide evidence for a survival advantage of 
patients undergoing trimodality treatment compared to double modality treatment.  
Fourth, we reported an average of 16.0% of lymph node metastasis at initial presentation for SNUC patients. 
There were also 26.9% of patients demonstrating regional failure at 2 years. Likewise, 8.1% of patients present 
with distant metastasis at diagnosis while 24.5% of patients had distant failure at 2 years follow-up. 
Substantiating previous reports[7], these data emphasize the importance of regional and distant disease 
assessment in SNUC patients and may encourage surgeons and radio-oncologist towards elective treatment of 
the neck. For squamous cell carcinoma e.g. of the oral cavity, elective treatment of the neck is usually 
recommended if the risk of nodal metastasis exceeds 15%[18]. Although data is yet insufficient to determine 
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which particular subgroup of SNUC patients are most likely to benefit from elective neck dissection, we 
believe that radiation field planning should include treatment of the neck. Furthermore, initial staging should 
always include assessment of distant disease. This meta-analysis shows that the most common distant sites are 
the lungs, followed by bone and liver. 
In conclusion, this study shows that SNUC is an aggressive malignancy occurring mostly in men, with frequent 
nodal and distant metastasis, that is best treated, as demonstrated in multivariable analysis, by at least double 
modality treatment. When surgery is offered for a patient with SNUC, radiotherapy should always be 
considered as part of treatment planning in the postoperative setting. Second, the adjunct of chemotherapy to 
radiotherapy seems to provide a survival advantage as well. However, we were not able to show an advantage 
in survival for triple modality treatment compared to double modality treatment. The exact role of 
chemotherapy should be investigated in future studies.  
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Table 2: Over view of studies included in the metaanalysis (29 studies; 390 patients) 
First author Pub Year  Journal Study University  City State Country Number p atients  Start year  End year  
Frie rson[ 1]  1986 Am J Surg Pathol  U of Virginia  Charlotte svi lle  VA USA  8 1942 1985 
Levine[19]  1987 Lary ngoscope  U of Virginia  Charlotte svi lle  VA USA  11 1975 1986 
Gallo[ 20]  1993 Ear Nose Throat J U of Florence  Florence  Toscany  Italy 13 1970 1990 
Gorel ick[11]  2000 Neurosurgery  U of Michiga n Ann Arbor MI USA  4 NA  NA  
Miyamoto[ 21]  2000 Lary ngoscope  U of Cincinnati  Cincinnati  IN USA  14 1970 1999 
Smith[22]  2000 Lary ngoscope  Mount S ina i  New York NY USA  6 NA  NA  
Heth[23]  2001 Skul l Base  U of Iowa  Iowa City  IA USA  9 1986 2001 
Musy[ 24]  2002 Lary ngoscope  U of Virginia  Charlotte svi lle  VA USA  15 1986 2000 
Jeng[ 25] 2002 Am J Surg Pathol  National Taiwa n Taipei  
 
Taiwan 36 NA  NA  
Norleza[26]  2004 Med J Malay sia  U Keba ng saan Kuala Lum pur Malaysia  9 1999 2003 
Rose ntha l[27]  2004 Cancer MD Anderson Houst on TX USA  16 1982 2002 
Kim[28]  2004 Am J Otola ry ngol  UCLA  Los Ange les CA USA  8 1995 2002 
Rischin[ 29]  2004 Head Neck Peter MacCallum CC Melbourne  
 
AUS  10 1990 2002 
Kramer[ 30]  2004 J Otola ry ngol  U of B ritish Colombia  Vancouver BC Canada  4 1986 2001 
Hoppe[ 31]  2006 Int J Radiat Onc ol Biol Phy s Memorial S loa n Kettering CC New York NY USA  4 1987 2005 
Chen[ 32]  2007 Int J Radiat Onc ol Biol Phy s Stanford Stanford CA USA  21 1990 2004 
Lin[ 33]  2009 Skul l ba se  U of Michiga n Ann Arbor MI USA  19 1995 2008 
Menon[34]  2010 Ind J Pathol Microbiol  Tata Memorial  Parel  Mumbai  India  5 2002 2007 
O'Reil ly[35]  2010 Lary ngoscope  Mayo Clinic Roche ster MN USA  12 1980 2006 
Revena ug h[36]  2011 Am J Otola ry ngol  U Texas South Weste rn Dalla s TX USA  13 2002 2009 
Xu[37] 2013 J Otola ry ngol Head Neck S urg  U of Albe rta Edmont on AL Canada  20 1986 2010 
Al-Mangami[ 38]  2013 Eur Arc h Otorhinolaryng ol  Erasmus Rotterdam  
 
N'la nds 21 1996 2010 
Moura d[17]  2013 Am J Clin Oncol  Yeshiva University  New York  NY USA  18 1997 2009 
Yoshida[ 39] 2013 Am J Otola ry ngol  Davis Sacramento CA USA  16 1999 2009 
van de r La nn[12]  2013 Eur Arc h Otorhinolaryng ol  U Groninge n Groningen 
 
N'la nds 8 1980 2010 
Christophe rson[ 40]  2014 Am J Otola ry ngol  U of Florida  Gaine sville  FL USA  23 1992 2010 
Lopez[41] 2015 Rhinology  Asturia s Ovie do 
 
Spain 17 2001 2013 
Gray[42]  2015 Head Neck Harvard Boston MA USA  19 1995 2013 
Morand 2017 present cases series  U of Zurich Zurich  Switzer' d 11 2001 2014 
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Table 1: Baseline characteristics, treatment and outcome of SNUC patients treated at Zurich University Hospital 
# Age 
(y) 
Sex Employement TNM Surgery IMRT 
(Gy)* 
Chemotherapy † Local 
recurrence 
(months) 
Regional 
recurrence 
(months) 
Distant 
metastasis 
(months, site ‡) 
Death 
(months) 
Follow-
up 
(months) 
1 
58 M 
Warehouseman T4N0M
0 
None 
68 Concomitant P 
Y (2) 
N N 13 13 
2 
53 F 
Office employee T4N0M
0 
None 
NA Induction TF 
N 
N N 2 2 
3 
51 M 
Mechanic T4N0M
0 
None 
70 Concomitant P 
N 
N Y (13, oss, hep) 17 17 
4 
33 M 
Printer T3N0M
0 
Endoscopi
c 70 Concomitant P  
N 
N N survived 22 
5 
57 M 
Janitor T4N0M
0 
Open 
63 Concomitant P  
Y (7) 
N Y (7, pulm, oss) 10 10 
6 
44 F 
Bank employee T3N0M
0 
Endoscopi
c 66 Concomitant P 
N 
N N survived 54 
7 
46 M 
Traveling 
salesman 
T4N0M
0 
Open 
60 Concomitant P 
N 
N N survived 108 
 
8 
50 F 
 
Bank employee 
 
T2N0M
0 
 
Open 
61.2 
Induction TPF 
+ Concomitant P 
 
Y (89) 
N N survived 99 
9 
65 M 
Ambassador T4N0M
0 
Open 
59.4 Concomitant P 
N 
Y (12) Y (12, pulm, oss) 13 13 
1
0 69 M 
Metallic hardware  T4N0M
0 
Open 
62 Concomitant P 
N 
N Y (19 pulm, oss) 74 74 
1
1 25 M 
Hotel industry T4N0M
0 
Open 
68.4 Concomitant P 
Y (4) 
Y (4) Y (6, pulm, oss) 7 7 
* IMRT: Intensity moduladed radiotherapy. Local doses shown. †: T: Taxane. P: Platin. F: 5-fluorouracil. ‡: oss: bone. hep: liver. pulm: lungs. NA: not available 
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Table 2: Overview of studies included in the metaanalysis (29 studies; 390 patients) 
First author Pub 
Year  
Journal Study University  City State Country Number 
patients 
Start 
year 
End 
year 
Frierson[1] 1986 Am J Surg Pathol U of Virginia Charlottesvill
e  
VA USA 8 1942 1985 
Levine[19] 1987 Laryngoscope U of Virginia Charlottesvill
e  
VA USA 11 1975 1986 
Gallo[20] 1993 Ear Nose Throat J U of Florence Florence Toscan
y 
Italy 13 1970 1990 
Gorelick[11] 2000 Neurosurgery U of Michigan Ann Arbor MI USA 4 NA NA 
Miyamoto[21] 2000 Laryngoscope U of Cincinnati Cincinnati IN USA 14 1970 1999 
Smith[22] 2000 Laryngoscope Mount Sinai New York NY USA 6 NA NA 
Heth[23] 2001 Skull Base U of Iowa Iowa City IA USA 9 1986 2001 
Musy[24] 2002 Laryngoscope U of Virginia Charlottesvill
e  
VA USA 15 1986 2000 
Jeng[25] 2002 Am J Surg Pathol National Taiwan Taipei 
 
Taiwan 36 NA NA 
Norleza[26] 2004 Med J Malaysia U Kebangsaan Kuala Lumpur Malaysia 9 1999 2003 
Rosenthal[27] 2004 Cancer MD Anderson Houston TX USA 16 1982 2002 
Kim[28] 2004 Am J Otolaryngol UCLA Los Angeles CA USA 8 1995 2002 
Rischin[29] 2004 Head Neck Peter MacCallum CC Melbourne 
 
AUS 10 1990 2002 
Kramer[30] 2004 J Otolaryngol U of British Colombia Vancouver BC Canada 4 1986 2001 
Hoppe[31] 2006 Int J Radiat Oncol Biol Phys Memorial Sloan 
Kettering CC 
New York NY USA 4 1987 2005 
Chen[32] 2007 Int J Radiat Oncol Biol Phys Stanford Stanford CA USA 21 1990 2004 
Lin[33] 2009 Skull base U of Michigan Ann Arbor MI USA 19 1995 2008 
Menon[34] 2010 Ind J Pathol Microbiol Tata Memorial Parel Mumbai India 5 2002 2007 
O'Reilly[35] 2010 Laryngoscope Mayo Clinic Rochester MN USA 12 1980 2006 
Revenaugh[36
] 
2011 Am J Otolaryngol U Texas South 
Western 
Dallas TX USA 13 2002 2009 
Xu[37] 2013 J Otolaryngol Head Neck 
Surg 
U of Alberta Edmonton AL Canada 20 1986 2010 
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Al-
Mangami[38] 
2013 Eur Arch Otorhinolaryngol Erasmus Rotterdam 
 
N'lands 21 1996 2010 
Mourad[17] 2013 Am J Clin Oncol Yeshiva University New York  NY USA 18 1997 2009 
Yoshida[39] 2013 Am J Otolaryngol Davis Sacramento CA USA 16 1999 2009 
van der 
Lann[12] 
2013 Eur Arch Otorhinolaryngol U Groningen Groningen 
 
N'lands 8 1980 2010 
Christopherso
n[40] 
2014 Am J Otolaryngol U of Florida Gainesville FL USA 23 1992 2010 
Lopez[41] 2015 Rhinology Asturias Oviedo 
 
Spain 17 2001 2013 
Gray[42] 2015 Head Neck Harvard Boston MA USA 19 1995 2013 
Morand 2017 present cases series U of Zurich Zurich  Switzer'
d 
11 2001 2014 
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Table 3: Disease-specific survival for each treatment combination 
Hazard 
ratio  
(95%-CI) 
P value 
UNADJUSTED/UNIVARIABLE ADJUSTED/MULTIVARIABLE (T, N, M, and age) 
Palliativ
e 
RT alone RT + 
Chemo 
Surgery 
alone 
Surgery + 
RT 
Surgery + 
RT + 
Chemo 
Palliativ
e 
RT alone RT + Chemo Surgery 
alone 
Surgery + 
RT 
Surgery + 
RT + Chemo 
Palliative 1 2.79  
(1.30-6.0) 
0.0087 
4.79  
(2.2-
10.46) 
0.000082 
3.56 
(1.44-
8.79) 
0.0058 
13.56  
(5.63-
32.68) 
0.00000000
62 
5.31  
(2.42-
11.66) 
0.000032 
1 2.67  
(0.73-9.8) 
0.14 
6.84  
(2.22-
21.10) 
0.00082 
2.70  
(0.69-
10.56) 
0.15 
10.60  
(2.77-
40.53) 
0.00056 
7.24  
(2.43-
21.61) 
0.00039 
RT alone  1 1.72  
(0.87-
3.39) 
0.12 
1.28 
(0.55-
2.96) 
0.57 
4.86  
(2.17-
10.90) 
0.00012 
1.90  
(0.97-
3.75) 
0.063 
 1 2.56  
(0.99-6.59) 
0.051 
1.01  
(0.32-3.21) 
0.98 
3.97  
(1.27-
12.42) 
0.018 
2.71  
(1.07-6.84) 
0.035 
RT + 
Chemo 
  1 0.74  
(0.33-
1.68) 
0.48 
2.83  
(1.34-5.98) 
0.0065 
1.11  
(0.62-
1.97) 
0.73 
  1 0.40 
(0.14-1.16) 
0.09 
1.55  
(0.58-4.13) 
0.38 
1.06  
(0.55-2.02) 
0.86 
Surgery 
alone 
   1 3.81  
(1.53-9.46) 
0.004 
1.49  
(0.67-
3.31) 
0.33 
   1 3.92  
(1.19-
12.92) 
0.025 
2.68  
(0.97-7.42) 
0.058 
Surgery + 
RT 
    1 0.39  
(0.18-
0.83) 
0.015 
    1 0.68  
(0.26-1.76) 
0.43 
Surgery + 
RT + 
Chemo 
     1 
 
     1 
 
RT= radiotherapy. Chemo= chemotherapy 
Hazard Ratio =  How much more likely is it to die of disease when you are in group *row* compared to group *column*  
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Table 4: Disease-specific survival according to n-modality of treatment 
Hazard ratio 
P value 
UNADJUSTED/UNIVARIABLE ADJUSTED/MULTIVARIABLE (T/Kadish, N, M, and age) 
Palliative Single modality Double modality Triple modality Palliative Single modality Double modality Triple modality 
Palliative 1 3.09  
(1.53-6.28) 
0.0018 
7.53  
(3.67-15.47) 
0.000000038 
5.66 
(2.63-12.17) 
0.000009 
1 2.55  
(0.78-8.41) 
0.12 
7.59  
(2.52-22.82) 
0.00031 
7.14  
(2.41-21.17) 
0.00039 
Single modality  1 2.43  
(1.42-4.18) 
0.0013 
1.83  
(1.02-3.28) 
0.042 
 1 2.97  
(1.41-6.27) 
0.0043 
2.80  
(1.29-6.05) 
0.009 
Double modality   1 0.75  
(0.44-1.27) 
0.29 
  1 0.94  
(0.52-1.7) 
0.84 
Triple modality    1 
 
   1 
Single modality: RT or surgery alone. Double modality: Combination of surgery & RT or RT & Chemo. Triple modality: Surgery & RT & Chemo 
Hazard Ratio =  How much more likely is it to die of disease when you are in group *row* compared to group *column*  
